<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039619</url>
  </required_header>
  <id_info>
    <org_study_id>WA42985</org_study_id>
    <secondary_id>2021-000097-29</secondary_id>
    <nct_id>NCT05039619</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis</brief_title>
  <acronym>POSTERITY</acronym>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the&#xD;
      safety, efficacy and pharmacokinetics of obinutuzumab in adolescent participants aged 12 to&#xD;
      less than 18 with biopsy-confirmed proliferative lupus nephritis (LN).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants who Achieve a Complete Renal Response (CRR)</measure>
    <time_frame>Week 76</time_frame>
    <description>CRR is defined as achievement of all of the following:&#xD;
Urinary protein-to-creatinine ratio (UPCR) &lt;0.5&#xD;
Estimated Glomerular Filtration Rate (eGFR) &gt;=85% of baseline&#xD;
No occurrence of intercurrent events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a CRR</measure>
    <time_frame>Weeks 24 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve a Partial Renal Response (PRR)</measure>
    <time_frame>Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an Overall Response (CRR or PRR)</measure>
    <time_frame>Weeks 24, 52, and 76</time_frame>
    <description>PRR is defined as:&#xD;
achievement of all of the following:&#xD;
&gt;=50% reduction in urinary protein-to-creatinine ratio (UPCR) from baseline&#xD;
UPCR &lt; 1 (or &lt; 3 if the baseline UPCR was &gt;=3)&#xD;
eGFR &gt;=85% of baseline&#xD;
No occurrence of intercurrent events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in UPCR</measure>
    <time_frame>Baseline to Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR</measure>
    <time_frame>Baseline to Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of CRR over the Course of 76 weeks</measure>
    <time_frame>Up to Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Experience Treatment Failure</measure>
    <time_frame>Week 12 to Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C3 Complement Levels</measure>
    <time_frame>Baseline to Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C4 Complement Levels</measure>
    <time_frame>Baseline to Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0</measure>
    <time_frame>Baseline to Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Obinutuzumab</measure>
    <time_frame>Baseline to Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving B-cell Depletion via Highly Sensitive Flow Cytometry (HSFC)</measure>
    <time_frame>Baseline, Weeks 4, 24, 52 and 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale (PedsQL)-Fatigue Total Score</measure>
    <time_frame>Baseline to Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)</measure>
    <time_frame>Baseline to Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Child Health Questionnaire-Parent Form 28 (CHQ-PF28) Domain Scores</measure>
    <time_frame>Baseline to Week 76</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1, Day 14, Week 24, Week 26 and Week 52. Participants with a body weight of 45 kg or more will receive the 1000 mg dose. Participants with a body weight below 45 kg will receive a weight adjusted dose of 20 mg/kilogram (kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo participants will receive obinutuzumab matched placebo on Day 1, Day 14, Week 24, Week 26 and Week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <other_name>Gazyva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen/paracetamol</intervention_name>
    <description>Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine hydrochloride (HCl)</intervention_name>
    <description>Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  International Society of Nephrology and the Renal Pathology Society (ISN/RPS) 2003&#xD;
             Class III or IV active LN demonstrated on renal biopsy performed in the 12 months&#xD;
             prior to or during screening&#xD;
&#xD;
          -  Class V disease may be present in addition to Class III or IV LN, but participants&#xD;
             with isolated Class V disease are not eligible&#xD;
&#xD;
          -  Diagnosis of SLE according to the Systemic Lupus International Collaborating Clinics&#xD;
             (SLICC) 2012 criteria&#xD;
&#xD;
          -  Significant proteinuria defined by a UPCR above &gt; 0.5 based on a first-morning void&#xD;
             (FMV) collection at screening&#xD;
&#xD;
          -  During the 12 months prior to or during screening, all participants must have received&#xD;
             at least one dose of pulse-range IV methylprednisolone (typically 30 mg/kg, maximum of&#xD;
             1000 mg per dose) or equivalent for the treatment of the current episode of active LN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe, active central nervous system (CNS) SLE, including retinitis, poorly&#xD;
             controlled seizure disorder, acute confusional state, myelitis, stroke, cerebellar&#xD;
             ataxia, or dementia&#xD;
&#xD;
          -  Sclerosis in &gt;50% of glomeruli on renal biopsy&#xD;
&#xD;
          -  Purely chronic Class III(c) or Class IV(c) disease on renal biopsy, defined as the&#xD;
             absence of any active lesions&#xD;
&#xD;
          -  Presence of rapidly progressive glomerulonephritis&#xD;
&#xD;
          -  Pure Class V LN&#xD;
&#xD;
          -  Intolerance or contraindication to study therapies&#xD;
&#xD;
          -  Active infection of any kind (excluding fungal infection of nail beds) or any major&#xD;
             episode of infection requiring hospitalization or treatment with IV anti-infective&#xD;
             medications within 4 weeks prior to screening, or completion of oral anti-infectives&#xD;
             within 2 weeks prior to randomization&#xD;
&#xD;
          -  History of or currently active primary or secondary immunodeficiency, including known&#xD;
             history of HIV infection and other severe Immunodeficiency blood disorders&#xD;
&#xD;
          -  History of serious recurrent or chronic infection&#xD;
&#xD;
          -  History of or current cancer, including solid tumors, hematological malignancies, and&#xD;
             carcinoma in situ (except basal cell carcinoma and squamous cell carcinoma of the skin&#xD;
             that have been excised and cured) within the past 5 years&#xD;
&#xD;
          -  Significant or uncontrolled concomitant medical disease which, in the investigator's&#xD;
             opinion, would preclude participant participation&#xD;
&#xD;
          -  Currently active alcohol or drug abuse or history of alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WA42985 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University health</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado, Anchutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory Children's Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta Center for Advanced Pediatrics; Allergy and Immunology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Health University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center of New York; Pediatrics</name>
      <address>
        <city>Queens</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ser Servicos Especializados Em Reumatologia</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>40150-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-888</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Sao Paulo - UNIFES</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04026-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - FMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré; Nephrologie pediatrique</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hop Necker Enfants Malades;UIH</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital des Enfants; Nephro - Rhumato - Medecine Interne - Hypertension</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu; U.O. Di Nefrologia E Dialisi</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS G. Gaslini; U.O. Nefrologia, Dialisi e Trapianto</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16148</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Pediatrica II De Marchi</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Ginecología y Reproducción</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica El Golf</name>
      <address>
        <city>San Isidro</city>
        <zip>L27 Lima</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne; Klinika Chorob Nerek i Nadciśnienia Dzieci i Mlodziezy</name>
      <address>
        <city>Gdansk</city>
        <zip>80-294</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny dla Dzieci i Doroslych; Oddzial Kliniczny Pediatrii i Nefrologii</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji; Klinika Reumatologii Wieku Rozwojowego</name>
      <address>
        <city>Warszawa</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Scientific Research Institute of Rheumatology&quot; of russian Academy of Medical Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SI Sceintific children health center RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State; Pediatrics Medical Academy</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Red Cross War Memorial Children's Hospital; Nephrology Unit</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital; Renal Unit</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Panaroma Medical Center; Clinical Trials Department</name>
      <address>
        <city>Panorama</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan De Deu; Servicio de Reumatologia Pediatrica</name>
      <address>
        <city>Esplugas DE Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal ; Servicio de Reumatologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de La Paz; Unidad de Reumatologia Pediatrica</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe: Servicio de Reumatologia Pediatrica</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hospital For Children</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alder Hey Childrens Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

